MAP2K7 and melanoma: Overall, inhibitor performance in melanoma is driven by molecular genotype and influenced by subtype, with BRAF/MEK inhibitors offering the strongest benefit in BRAF V600–mutant cutaneous disease and KIT inhibitors providing a limited but targeted option for select non-cutaneous subtypes [4].